Roundhill believes that weight loss drugs, including GLP-1 agonists, represent one of the most revolutionary advancements in the global pharmaceuticals industry. The Roundhill GLP-1 & Weight Loss ETF (“OZEM”) is the world’s first GLP-1 ETF. OZEM is an actively-managed ETF.
Roundhill Investments - GLP-1 & Weight Loss ETF · Issued by Roundhill
| NVO | Novo Nordisk AS ADR | 12.05% |
| LLY | Eli Lilly and Co | 12.02% |
| PFE | Pfizer Inc | 7.42% |
| 1093.HK | CSPC Pharmaceutical Group Ltd | 6.91% |
| VKTX | Viking Therapeutics Inc | 4.84% |
| 128940.KQ | Hanmi Pharm Co Ltd | 4.82% |
| AMGN | Amgen Inc | 4.49% |
| KLRA | Kailera Therapeutics Inc | 4.27% |
| 4519.T | Chugai Pharmaceutical Co Ltd | 4.12% |
| ZEAL.CO | Zealand Pharma AS | 4.06% |
No recent news for OZEM. The ingest cron pulls every 15 minutes during market hours.